Division of Hematology, Mayo Clinic, Rochester, MN.
Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN.
Blood. 2024 Aug 15;144(7):790-793. doi: 10.1182/blood.2024024623.
The survival of patients achieving a cardiac complete response in light chain amyloidosis, defined as N-terminal pro B-type natriuretic peptide ≤350 pg/mL or B-type natriuretic peptide ≤80 pg/mL, was similar to that of a matched general population, with estimated 5-year survival rates of 93% and 95%, respectively.
在轻链淀粉样变性中,达到心脏完全缓解的患者(定义为 N-末端 pro B 型利钠肽 ≤350pg/mL 或 B 型利钠肽 ≤80pg/mL)的存活率与匹配的一般人群相似,估计 5 年存活率分别为 93%和 95%。